Alkem Laboratories has acquired an additional stake in its subsidiary, Enzene Biosciences Limited, by purchasing 64,02,018 equity shares for ₹299,99,85,634.80. This acquisition increases Alkem’s shareholding in Enzene to 99.61%. The investment aims to support Enzene’s capital expenditure and working capital needs, reinforcing Alkem’s commitment to its biologics and biosimilars business.
Increased Investment in Enzene Biosciences
Alkem Laboratories has increased its stake in its subsidiary, Enzene Biosciences Limited, through a rights issue. The company acquired 64,02,018 equity shares. This transaction was completed on December 26, 2025.
Details of the Share Acquisition
The equity shares were acquired at a price of ₹468.60 per share, totaling an investment of ₹299,99,85,634.80. Following this acquisition, Alkem Laboratories now holds 99.61% of Enzene’s equity share capital.
Strategic Rationale
This investment in Enzene Biosciences is intended to bolster its capital expenditure and working capital. Enzene is engaged in research and development, manufacturing, and out-licensing of biosimilar products, as well as contract development and manufacturing for biosimilars and novel biologics.
Enzene’s Financial Performance
Enzene Biosciences Limited has demonstrated significant revenue growth in recent years. The company’s turnover for the past three financial years is as follows:
- FY 2024-2025: ₹363.62 crores
- FY 2023-2024: ₹262.66 crores
- FY 2022-2023: ₹144.00 crores
Source: BSE
